Financial insights of OTLC

MyFinsight

For the quarter ending 2026-03-31.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Research and development	795	3,272.5*	426	297
General and administrative	1,852,590	2,347,913.5*	490,547	65,672
Total operating expenses	1,853,385	2,351,186	490,973	65,969
Loss from operations	-1,853,385	-2,351,186*	-490,973	-65,969
Change in fair value of investment in gmp bio	-	281,688,498.25*	-	-
Interest expense, net	295,811	226,811*	231,338	207,780
Loss on debt conversion	-	-1,058,976*	-	0
Change in fair value of derivative on debt	-90,080	215,362*	-392,058	484,198
Reimbursement for expenses - related party	-	-	-	0
Miscellaneous income	-	1,407.75*	-	-
Total other expense	-385,891	280,619,481*	-623,396	276,418
Net income (loss) before income taxes	-	278,268,295*	-	-
Provision for income taxes	-	27,887,500*	-	-
Net loss before non-controlling interests	-2,239,276	250,380,795*	-1,114,369	210,449
Net loss attributable to non-controlling interests	-45,500	-53,300.5*	-67,004	-67,407
Net loss attributable to oncotelic therapeutics, inc	-2,193,776	250,434,095.5	-1,047,365	277,856

Basic EPS	0	0.585	0	0
Diluted EPS	0	0.639	-	0
Basic Average Shares	443,801,416	428,408,639	426,435,213	408,292,720
Diluted Average Shares	443,801,416	391,660,436	-	452,809,058